20389usd
3,1 %
Date:2026-04-29Time:23:00:00Latest report:Q4-2025List:NYSETicker:ABBV
Market Cap:360 681 musdEnterprise Value:422 920 musdNet Sales:61 160 musdEarnings:4 226 musdEmployees:0ISIN:US00287Y1091

Ratios

10-year key figure history for AbbVie Inc turnover, profit, dividend, equity, PE and PB.

Pro
Pro

Stockprice

Price movement for AbbVie Inc with index and moving average MA50 and MA200.

Stockprice:203,89
MA50:215,24
MA200:217,94
Price/MA200:-6,4 %
RSI (14):45,5
Price/MA50:-5,3 %

Description

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.